PrimeRFP SCOUT · Federal Contract Recompete Brief

75N92026P00029Medication - phenburane — Medunik Usa Inc

Medunik Usa Inc holds $210K across 3 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2026 PoP end — agencies typically plan 12–18 months ahead.

National Institutes Of Health Nhlbi

Awarding office

Medunik Usa Inc

Recipient

Dec 31, 2026

PoP end

$210K

Obligated

$210K

Potential

325412

NAICS

6505

PSC

NONE

Set-aside

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Medunik Usa Inc — $90

Contract facts

NONE

Contract number75N92026P00029

AgencyNational Institutes Of Health Nhlbi

Awarding officeNational Institutes Of Health Nhlbi

Awarding agencyDepartment of Health and Human Services (HHS)

Funding agencyDepartment of Health and Human Services (HHS)

IncumbentMedunik Usa Inc

CAGE86QL6

UEIDND9H4EQ14T5

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Place of performancePRINCETON NJ

Pricing typeFirm Fixed Price

Extent competedNot Competed Under SAP

Related solicitation75N92026Q00008

PoP startDec 19, 2025

PoP end (current)Dec 31, 2026

Obligated$210K

Current value$210K

Potential value$210K

MEDICATION - PHENBURANE is a federal NONE award for National Institutes Of Health Nhlbi held by Medunik Usa Inc. Estimated value $210K ($210K obligated). Current period of performance ends Dec 31, 2026. Last award drew 1 bidder. Place of performance: PRINCETON NJ. Related solicitation 75N92026Q00008.

Recompete timing

Public

● Expiring in 133 days

Current PoP ends Dec 31, 2026 (133 days remaining). Agencies typically plan 12–18 months ahead — at 4.4 months out, that window is already open. The buying decision is likely already in motion.

Incumbent footprint

Public record

Medunik Usa Inc — $210K obligated across 3 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)

Department of Health and Human Services (HHS)$210K · 100% of firm total

Open full company profile →

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 75N92026P00029?

75N92026P00029 (Medication - phenburane) is a National Institutes Of Health Nhlbi award with a potential value of $210K, currently held by Medunik Usa Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded 75N92026P00029?

National Institutes Of Health Nhlbi awarded 75N92026P00029 to Medunik Usa Inc (potential $210K).

Who is the incumbent on 75N92026P00029?

Medunik Usa Inc is the incumbent with $210K across 3 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2026.

When does Medunik Usa Inc’s 75N92026P00029 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Aug 19, 2026 · refreshed monthlyLatest procurement action Jan 23, 2026